De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR1/HER21 Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

Harbeck, Nadia; Nitz, Ulrike A.; Christgen, Matthias; Kuemmel, Sherko; Braun, Michael; Schumacher, Claudia; Potenberg, Jochem; Tio, Joke; Aktas, Bahriye; Forstbauer, Helmut; Grischke, Eva-Maria; Scheffen, Iris; Malter, Wolfram; von Schumann, Raquel; Just, Marianne; zu Eulenburg, Christine; Biehl, Claudia; Kolberg-Liedtke, Cornelia; Deurloo, Regula; de Haas, Sanne; Jozwiak, Katarzyna; Hauptmann, Michael; Kates, Ronald; Graeser, Monika; Wuerstlein, Rachel; Kreipe, Hans H.; Gluz, Oleg

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR1/HER21 Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

Autor(en):

Harbeck, Nadia; Nitz, Ulrike A.; Christgen, Matthias; Kuemmel, Sherko; Braun, Michael; Schumacher, Claudia; Potenberg, Jochem; Tio, Joke; Aktas, Bahriye; Forstbauer, Helmut; Grischke, Eva-Maria; Scheffen, Iris; Malter, Wolfram; von Schumann, Raquel; Just, Marianne; zu Eulenburg, Christine; Biehl, Claudia; Kolberg-Liedtke, Cornelia; Deurloo, Regula; de Haas, Sanne; Jozwiak, Katarzyna; Hauptmann, Michael; Kates, Ronald; Graeser, Monika; Wuerstlein, Rachel; Kreipe, Hans H.; Gluz, Oleg

Tübinger Autor(en):

Grischke, Eva-Maria

Erschienen in:

Journal of Clinical Oncology (2023), Bd. 41, H. 22, S. 3796-3804

Verlagsangabe:

Philadelphia : Lippincott Williams & Wilkins

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1200/JCO.22.01816

ISSN:

0732-183X